Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q1 EPS of ($1.31), $0.03 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.1 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.